Novel investigational adenosine A_2A receptor antagonists for Parkinson's disease

Bibliography

• Obeso JA, Rodriguez-Oroz MC, Rodriguez M, Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci 2000;23:S8-19
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Healy DG, Schapira AH; National Institute for Clinical Excellence. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006;5(3):235-45
   PubMed Web of Science ®Google Scholar
• Alves G, Forsaa EB, Pedersen KF, Epidemiology of Parkinson's disease. J Neurol 2008;255(Suppl 5):18-32
   PubMedGoogle Scholar
• Jenner P, Olanow CW. The pathogenesis of cell death in Parkinson's disease. Neurology 2006;66:S24-36
   PubMed Web of Science ®Google Scholar
• Twelves D, Perkins KS, Counsell C. Systematic review of incidence studies of Parkinson's disease. Mov Disord 2003;18(1):19-31
   PubMed Web of Science ®Google Scholar
• von Campenhausen S, Bornschein B, Wick R, Prevalence and incidence of Parkinson's disease in Europe. Eur Neuropsychopharmacol 2005;15(4):473-90
   PubMed Web of Science ®Google Scholar
• Van Den Eeden SK, Tanner CM, Bernstein AL, Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 2003;157(11):1015-22
   PubMed Web of Science ®Google Scholar
• Weintraub D, Comella CL, Horn S. Parkinson's disease–Part 1: pathophysiology, symptoms, burden, diagnosis, and assessment. Am J Manag Care 2008;14:S40-8
   PubMed Web of Science ®Google Scholar
• Dorsey ER, Constantinescu R, Thompson JP, Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007;68:384-86
   PubMed Web of Science ®Google Scholar
• Dowding CH, Shenton CL, Salek SS. A review of the health-related quality of life and economic impact of Parkinson's disease. Drugs Aging 2006;23(9):693-721
   PubMed Web of Science ®Google Scholar
• Olanow CW, Agid Y, Mizuno Y, Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord 2004;19(9):997-1005
   PubMed Web of Science ®Google Scholar
• Horstink M, Tolosa E, Bonuccelli U, Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease. Eur J Neurol 2006;13(11):1170-85
   PubMed Web of Science ®Google Scholar
• Horstink M, Tolosa E, Bonuccelli U, Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's disease. Eur J Neurol 2006;13(11):1186-202
   PubMed Web of Science ®Google Scholar
• Guttman M, Kish SJ, Furukawa Y. Current concepts in the diagnosis and management of Parkinson's disease. CMAJ 2003;168(3):293-301
   PubMed Web of Science ®Google Scholar
• Goetz CG, Poewe W, Rascol O, Sampaio C. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord 2005;20(5):523-39
   PubMed Web of Science ®Google Scholar
• Morelli M, Di Paolo T, Wardas J, Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications. Prog Neurobiol 2007;83(5):293-309
   PubMed Web of Science ®Google Scholar
• Xu K, Bastia E, Schwarzschild M. Therapeutic potential of adenosine A(2A) receptor antagonists in Parkinson's disease. Pharmacol Ther 2005;105:267-310
   PubMed Web of Science ®Google Scholar
• Schiffmann SN, Vanderhaeghen JJ. Adenosine A2 receptors regulate the gene expression of striatopallidal and striatonigral neurons. J Neurosci 1993;13:1080-7
   PubMed Web of Science ®Google Scholar
• Svenningsson P, Le Moine C, Aubert I, Cellular distribution of adenosine A2A receptor mRNA in the primate striatum. J Comp Neurol 1998;399:229-40
   PubMed Web of Science ®Google Scholar
• Simola N, Morelli M, Pinna A. Adenosine A2A receptor antagonists and Parkinson's disease: state of the art and future directions. Curr Pharm Des 2008;14(15):1475-89
   PubMed Web of Science ®Google Scholar
• Pinna A, Di Chiara G, Wardas J, Morelli M. Blockade of A2A adenosine receptors positively modulates turning behaviour and c-fos expression induced by D1 agonists in dopamine-denervated rats. Eur J Neurosci 1996;8:1176-81
   PubMed Web of Science ®Google Scholar
• Pollack AE, Fink JS. Synergistic interaction between an adenosine antagonist and a D1 dopamine agonist on rotational behaviour and striatal c-Fos induction in 6-hydroxydopamine-lesioned rats. Brain Res 1996;743:124-30
   PubMed Web of Science ®Google Scholar
• Jenner P, Mori A, Hauser R, Adenosine, adenosine A(2A) antagonists, and Parkinson's disease. Parkinsonism Relat Disord 2009, May 13. PubMed PMID: 19446490. [Epub ahead of print]
   Google Scholar
• Fuxe K, Marcellino D, Genedani S, Agnati L. Adenosine A(2A) receptors, dopamine D(2) receptors and their interactions in Parkinson's disease. Mov Disord 2007;22(14):1990-2017
   PubMed Web of Science ®Google Scholar
• Ross GW, Abbott RD, Petrovitch H, Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 2000;283:2674-9
   PubMed Web of Science ®Google Scholar
• Ascherio A, Zhang SM, Hernán MA, Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann Neurol 2001;50:56-63
   PubMed Web of Science ®Google Scholar
• Chen JF, Xu K, Petzer JP, Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci 2001;21:RC143
   PubMed Web of Science ®Google Scholar
• Kalda A, Yu L, Oztas E, Chen JF. Novel neuroprotection by caffeine and adenosine A(2A) receptor antagonists in animal models of Parkinson's disease. J Neurol Sci 2006;248(1-2):9-15
   PubMed Web of Science ®Google Scholar
• Barcia C, Sánchez Bahillo A, Fernández-Villalba E, Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure. Glia 2004;46:402-9
   PubMed Web of Science ®Google Scholar
• Hunot S, Hirsch EC. Neuroinflammatory processes in Parkinson's disease. Ann Neurol 2003;53:S49-58
   PubMed Web of Science ®Google Scholar
• McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988;38:1285-91
   PubMed Web of Science ®Google Scholar
• Wu DC, Jackson-Lewis V, Vila M, Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 2002;22:1763-71
   PubMed Web of Science ®Google Scholar
• Ikeda K, Kurokawa M, Aoyama S, Kuwana Y. Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease. J Neurochem 2002;80:262-70
   PubMed Web of Science ®Google Scholar
• Pierri M, Vaudano E, Sager T, Englund U. KW-6002 protects from MPTP induced dopaminergic toxicity in the mouse. Neuropharmacology 2005;48:517-24
   PubMed Web of Science ®Google Scholar
• Chen JF, Sonsalla PK, Pedata F, Adenosine A2A receptors and brain injury: broad spectrum of neuroprotection, multifaceted actions and “fine tuning” modulation. Prog Neurobiol 2007;83(5):310-31
   PubMed Web of Science ®Google Scholar
• Takahashi RN, Pamplona FA, Prediger RD. Adenosine receptor antagonists for cognitive dysfunction: a review of animal studies. Front Biosci 2008;13:2614-32
   PubMed Web of Science ®Google Scholar
• Kase H, Aoyama S, Ichimura M, Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease. Neurology 2003;61(11Suppl 6):S97-100
   PubMedGoogle Scholar
• Jenner P. Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's disease. Expert Opin Investig Drugs 2005;14:729-38
   PubMed Web of Science ®Google Scholar
• FDA Issues Not Approvable Letter for Istradefylline. Available from: http://www.drugs.com/nda/kw_6002_080228.html [Last accessed 16 June 2009]
   Google Scholar
• Hockemeyer J, Burbiel JC, Mueller CE. Multigram-scale syntheses, stability, and photoreactions of A2A adenosine receptor antagonists with 8-styrylxanthine structure: potential drugs for Parkinson's disease. J Org Chem 2004;69(10):3308-18
   PubMed Web of Science ®Google Scholar
• Johnston TH, Brotchie JM. Drug in development for Parkinson's disease: an update. Curr Opin Investig Drugs 2006;7(1):25-32
   PubMed Web of Science ®Google Scholar
• Weiss SM, Benwell K, Cliffe IA, Discovery of nonxanthine adenosine A2A receptor antagonists for the treatment of Parkinson's disease. Neurology 2003;61(11 Suppl 6):S101-6
   PubMedGoogle Scholar
• Gillespie RJ, Bamford SJ, Botting R, Antagonists of the Human A2A Adenosine Receptor. 4. Design, Synthesis, and Preclinical Evaluation of 7-Aryltriazolo[4,5-d]pyrimidines. J Med Chem 2009;52(1):33-47
   PubMed Web of Science ®Google Scholar
• Product Pipeline of Vernalis. Parkinson's Disease: V2006. Available from: http://www.vernalis.com/ver/rdc2/neurology/v2006/ [Last accessed 16 June 2009]
   Google Scholar
• Padfield A, Denny S, Merrett A, Pre-clinical drug metabolism and pharmacokinetic studies with BIIB014/V2006. Presented at International research conference “Targeting adenosine A2A receptors in PD and other CNS Disorders”, Boston, USA (17-19 May 2006). Available from: http://handle.dtic.mil/100.2/ADA452764 [Last accessed 16 June 2009]
   Google Scholar
• Wade A, Bakhtyari A, Thomas R, BIIB014/V2006: Pharmacokinetics in young and elderly healthy subjects. Presented at International research conference “Targeting adenosine A2A receptors in PD and other CNS Disorders”, Boston, USA (17-19 May 2006). Available from: http://handle.dtic.mil/100.2/ADA452764 [Last accessed 16 June 2009]
   Google Scholar
• An Open-Label, Positron Emission Tomography Study to Assess Adenosine A2A Brain Receptor Occupancy of BIIB014 at Multiple Dose Levels in Healthy Male Volunteers. ClinicalTrials.gov. NCT00531193. Available from: http://clinicaltrials.gov/ct2/show/NCT00531193 [Last accessed 16 June 2009]
   Google Scholar
• Moresco RM, Todde S, Belloli S, In vivo imaging of adenosine A2A receptors in rat and primate brain using [11C]SCH442416. Eur J Nucl Med Mol Imaging 2005;32(4):405-13
   PubMed Web of Science ®Google Scholar
• Lightowler S, Knight AR, Upton R, Pharmacology of BIIB014/V2006, an A2A antagonist for the treatment of PD. Presented at International research conference “Targeting adenosine A2A receptors in PD and other CNS Disorders”, Boston, USA (17-19 May 2006). Available from: http://handle.dtic.mil/100.2/ADA452764 [Last accessed 16 June 2009]
   Google Scholar
• A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of Single and Multiple Oral Dose Administration of BIIB014 in Subjects With Moderate to Late Stage Parkinson's Disease Who Are Also Receiving Treatment With Levodopa ClinicalTrials.gov. NCT00438607. Available from: http://clinicaltrials.gov/ct2/show/NCT00438607 [Last accessed 16 June 2009]
   Google Scholar
• A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of Multiple Doses of BIIB014 Administered Orally in Subjects With Early Parkinson's Disease. ClinicalTrials.gov. NCT00442780. Available from: http://clinicaltrials.gov/ct2/show/NCT00442780 [Last accessed 16 June 2009]
   Google Scholar
• Biogen Idec reports favourable data from Phase IIa Parkinson's Disease studies of BIIB014 (licensed from Vernalis). Available from: http://www.vernalis.com/ver/nc/latestreleases/releases2009/2009-03-27/ [Last accessed 16 June 2009]; Access the Biogen IDEC results of presentation from: http://library.corporate-ir.net/library/14/148/148682/items/329869/503E91BE-5BE4-47F0-A030-17858A19C307_6_BIIB014v2.pdf [Last accessed 16 June 2009]
   Google Scholar
• Lightowler S. Progressing the A2A antagonist BIIB014/V2006 to the clinic for the treatment of PD. Presented at International research conference “Targeting adenosine A2A receptors in PD and other CNS Disorders”, Boston, USA (17-19 May 2006). Available from: http://handle.dtic.mil/100.2/ADA452764 [Last accessed 16 June 2009]
   Google Scholar
• Neustadt BR, Hao J, Lindo N, Potent, selective, and orally active adenosine A2A receptor antagonists: Arylpiperazine derivatives of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines. Bioorg Med Chem Lett 2007;17:1376-80
   PubMed Web of Science ®Google Scholar
• Ongini E, Dionisotti S, Gessi S, Comparison of CGS 15943, ZM 241385 and SCH 58261 as antagonists at human adenosine receptors. Naunyn Schmiedebergs Arch Pharmacol 1999;359(1):7-10
   PubMed Web of Science ®Google Scholar
• Fenu S, Pinna A, Ongini E, Morelli M. Adenosine A2A receptor antagonism potentiates L-DOPA induced turning behavior and c-fos expression in 6-hydroxydopamine-lesioned rats. Eur J Pharmacol 1997;321:143-47
   PubMed Web of Science ®Google Scholar
• Svenningsson P, Nomikos GG, Ongini E, Fredholm BB. Antagonism of adenosine A2A receptors underlies the behavioural activating effect of caffeine and is associated with reduced expression of messenger RNA for NGFI-A and NGFI-B in caudate-putamen and nucleus accumbens. Neuroscience 1997;79(3):753-64
   PubMed Web of Science ®Google Scholar
• Wardas J, Konieczny J, Lorenc-Koci E. SCH 58261, an A(2A) adenosine receptor antagonist, counteracts parkinsonian-like muscle rigidity in rats. Synapse 2001;41(2):160-71
   PubMed Web of Science ®Google Scholar
• Carta AR, Pinna A, Tronci E, Morelli M. Adenosine A2A and dopamine receptor interactions in basal ganglia of dopamine denervated rats. Neurology 2003;61:S39-43
   PubMedGoogle Scholar
• Simola N, Fenu S, Baraldi PG, Blockade of adenosine A2A receptors antagonizes parkinsonian tremor in the rat tacrine model by an action on specific striatal regions. Exp Neurol 2004;189:182-8
   PubMed Web of Science ®Google Scholar
• Pinna A, Pontis S, Borsini F, Morelli M. Adenosine A2A receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6-hydroxydopamine rat model of Parkinson's disease. Synapse 2007;61:606-14
   PubMed Web of Science ®Google Scholar
• Cutler DL, Tendolkar A, Hunter J. Effects of age and gender on preladenant pharmacokinetics in healthy subjects. Presented at Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movements Disorders, Paris, France (7-11 June 2009). Abstract Mo-194
   Google Scholar
• Brooks DJ, Warrington S, Tendolkar A, Positron emission tomography (PET) study of preladenant in healthy male subjects. Presented at Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movements Disorders, Paris, France (7-11 June 2009). Abstract Mo-187
   Google Scholar
• Hodgson RA, Bertorelli R, Varty GB, Characterization of the Potent and Highly Selective A2A Receptor Antagonists Preladenant and SCH 412348 in Rodent Models of Movement Disorders and Depression. J Pharmacol Exp Ther 2009 Mar 30. PubMed PMID: 19332567. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Hunter J. SCH 420814: a novel Adenosine A2a antagonist. Exploring Parkinson's Disease and beyond. Presented at International research conference “Targeting adenosine A2A receptors in PD and other CNS Disorders”, Boston, USA (17-19 May 2006). Available from: http://handle.dtic.mil/100.2/ADA452764
   Google Scholar
• Phase 2, 12-Week, Double-Blind, Dose-Finding, Placebo-Controlled Study to Assess the Efficacy and Safety of a Range of SCH 420814 Doses in Subjects With Moderate to Severe Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesias. ClinicalTrials.gov. NCT00406029. Available from: http://clinicaltrials.gov/ct2/show/NCT00406029 [Last accessed 18 June 2009]
   Google Scholar
• Hauser RA, Pourcher E, Micheli F, Efficacy of preladenant, a novel A2A antagonist, as an adjunct to levodopa for the treatment of Parkinson's disease. Presented at Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movements Disorders, Paris, France (7-11 June 2009). Abstract Tu-185
   Google Scholar
• Huyck SB, Wolski K, Cantillon M. Impact of A2A receptor antagonist preladenant on dyskinesia in moderate to severe Parkinson's disease: Post-hoc analysis of dose-finding study. Presented at Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movements Disorders, Paris, France (7-11 June 2009). Abstract Tu-187
   Google Scholar
• A Phase 2, 36-Week, Open-Label, Uncontrolled Safety Follow-up Study Assessing SCH 420814 5 mg BID (Protocol No. P05175). ClinicalTrials.gov. NCT00406029. Available from: http://clinicaltrials.gov/ct2/show/NCT00537017 [Last accessed 18 June 2009]
   Google Scholar
• Acute Effects of SCH 420814 on Dyskinesia and Parkinsonism in Levodopa Treated Patients. ClinicalTrials.gov. NCT00845000. Available from: http://clinicaltrials.gov/ct2/show/NCT00845000 [Last accessed 18 June 2009]
   Google Scholar
• Pourcher E, Micheli F, Mok V, Safety and tolerability profile of preladenant as an adjunct to L-dopa in patients with Parkinson's disease. Presented at Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movements Disorders, Paris, France (7-11 June 2009). Abstract We-187
   Google Scholar
• Minetti P, Tinti MA, Carminati P, 2-n-Butyl-9-8-[1,2,3] triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization. J Med Chem 2005;48:6887-96
   PubMed Web of Science ®Google Scholar
• Stasi MA, Borsini F, Varani K, ST1535: A preferential A2a adenosine receptor antagonist. Int J Neuropsychopharm 2006;9(5):575-84
   PubMed Web of Science ®Google Scholar
• Rose S, Ramsay Croft N, Jenner P. The novel adenosine A2a antagonist ST1535 potentiates the effects of a threshold dose of l-dopa in unilaterally 6-OHDA-lesioned rats. Brain Res 2007;1133:110-14
   PubMed Web of Science ®Google Scholar
• Tronci E, Simola N, Borsini F, Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats. Eur J Pharmacol 2007;566:94-102
   PubMed Web of Science ®Google Scholar
• Rose S, Jackson MJ, Smith LA, The novel adenosine A2a antagonist ST1535 potentiates the effects of a threshold dose of L-dopa in MPTP treated common marmosets. Eur J Pharmacol 2006;546(1-3):82-7
   PubMed Web of Science ®Google Scholar
• Galluzzo M, Pintor A, Pèzzola A, Behavioural and neurochemical characterization of the adenosine A2A receptor antagonist ST1535. Eur J Pharmacol 2008;579(1-3):149-52
   PubMed Web of Science ®Google Scholar
• Di Serio S, Danese V, Guaraldi D, The novel adenosine A2A receptor antagonist 2-butyl-9-methyl-8-(2H-1,2, 3-triazol-2-yl)-9H-purin-6-ylamine (ST1535) ameliorates memory disruption mediated by adenosine A1 receptor stimulation. Presented at 13th European Behavioural Pharmacology Society Biennial Meeting, Rome, Italy (4-7 September 2009)
   Google Scholar
• Sigma-Tau communication about development of ST-1535. Available from: http://www.sigma-tau.it/eng/fasidisviluppo.asp [Last accessed 18 June 2009] with specific piece of information provide by Sigma-Tau Company
   Google Scholar
• Schering Plough Corp. communication about preladenant clinical development program in PD. Available from: http://www.medicalnewstoday.com/articles/130623.php [Last accessed 18 June 2009]
   Google Scholar
• Kanda T, Tashiro T, Kuwana Y, Jenner P. Adenosine A2A receptors modify motor function in MPTP-treated common marmosets. Neuroreport 1998;9:2857-60
   PubMed Web of Science ®Google Scholar
• Kanda T, Jackson MJ, Smith LA, Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp Neurol 2000;162:321-27
   PubMed Web of Science ®Google Scholar
• Grondin R, Bedard PJ, Hadj Tahar A, Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys. Neurology 1999;52:1673-7
   PubMed Web of Science ®Google Scholar
• Shiozaki S, Ichikawa S, Nakamura J, Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology 1999;147:90-5
   PubMed Web of Science ®Google Scholar
• Bara-Jimenez W, Sherzai A, Dimitrova T, Adenosine A(2A) receptor antagonist treatment of Parkinson's disease. Neurology 2003;61:293-6
   PubMed Web of Science ®Google Scholar
• Levin BE, Katzen HL. Early cognitive changes and nondementing behavioral abnormalities in Parkinson's disease. Adv Neurol 2005;96:84-94
   PubMedGoogle Scholar
• El Yacoubi M, Ledent C, Parmentier M, Adenosine A2A receptor antagonists are potential antidepressants: evidence based on pharmacology and A2A receptor knockout mice. Br J Pharmacol 2001;134:68-77
   PubMed Web of Science ®Google Scholar
• Gessi S, Varani K, Merighi S, A(2A) adenosine receptors in human peripheral blood cells. Br J Pharmacol 2000;129:2-11
   PubMed Web of Science ®Google Scholar
• Haskó G, Pacher P. A2A receptors in inflammation and injury: lessons learned from transgenic animals. J Leukoc Biol 2008;83(3):447-55
   PubMed Web of Science ®Google Scholar
• Ohta A, Sitkovsky M. Role of G-protein-coupled adenosine receptors in down regulation of inflammation and protection from tissue damage. Nature 2001;414:916-20
   PubMed Web of Science ®Google Scholar
• Ohta A, Lukashev D, Jackson EK, 1,3,7-trimethylxanthine (caffeine) may exacerbate acute inflammatory liver injury by weakening the physiological immunosuppressive mechanism. J Immunol 2007;179(11):7431-8
   PubMed Web of Science ®Google Scholar
• Thiel M, Chouker A, Ohta A, Oxygenation inhibits the physiological tissue-protecting mechanism and thereby exacerbates acute inflammatory lung injury. PLoS Biol 2005;3(6):e174
   PubMedGoogle Scholar
• Mihara T, Mihara K, Yarimizu J, Pharmacological characterization of a novel, potent adenosine A1 and A2A receptor dual antagonist, 5-[5-amino-3-(4-fluorophenyl)pyrazin- 2-yl]-1-isopropylpyridine-2(1H)-one(ASP5854), in models of Parkinson's disease and cognition. J Pharmacol Exp Ther 2007;323(2):708-19
   PubMed Web of Science ®Google Scholar